Abstract: The present application provides use of Compound (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof in manufacture of a medicament useful in treating a disease related to high expression or abnormal activation of JAK and SYK kinases, comprising an autoimmune disease, such as an immune-mediated skin disease, in particular psoriasis, atopic dermatitis and SLE. Compound (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention can improve the skin lesions in mice with psoriasis, atopic dermatitis and SLE, alleviate the injury of kidney, inhibit the expansion of immune organs, reduce the level of inflammation, inhibit the increase of SLE related antibodies and cytokines in serum, and has a certain safe therapeutic window, which has a good clinical application prospect.

Abstract: Disclosed in some examples are methods, systems, and machine readable mediums which provide summaries of topics determined within a corpus of documents. These summaries may be used by customer service associates, analysts, or other users to quickly determine both topics discussed and contexts of those topics over a large corpus of text. For example, a corpus of documents may be related to customer complaints and the topics may be summarized to produce summaries such as “credit report update due to stolen identity.” These summarizations may be used to efficiently spot trends and issues.

Abstract: The present application provides application of butylphthalide or optical isomer, prodrug, deuterium, metabolite, and ring-opening product or ring-opening product salt thereof in the preparation of a drug for preventing, alleviating, or treating peripheral neuropathy, especially chemotherapy-induced peripheral neuropathy, and a use method of butylphthalide and a derivative thereof in preventing or treating peripheral neuropathy, especially chemotherapy-induced peripheral neuropathy. In vivo and in vitro studies show that the drug of the present invention can effectively prevent, alleviate, or treat peripheral neuropathy caused by chemotherapy drugs without affecting the tumor-inhibiting efficacy and pharmacokinetic properties of the chemotherapy drugs.

Abstract: The present invention sets forth a salt of an aldose reductase inhibitor shown in formula A-N. The salt being able to be prepared as a crystal form, having notably improved solubility relative to the compound of formula A, having lower hygroscopicity allowing for stable existence, and thus being more easily made into a medicine than are the formula A compound or other salts.

Abstract: Disclosed are a pharmaceutically acceptable salt of a heterocyclic compound depicted by formula (A) or a hydrate of the salt. The pharmaceutically acceptable salt is selected from alkali metal salts. The present inventors have unexpectedly discovered that three salts, especially sodium salt, lithium salt and a hydrate of either salt, have improved solubility and dissolution when compared to the compound of formula A, and thus can be more easily formulated into a drug product when compared to the compound of formula A. Also disclosed is a use of the heterocyclic compound or a hydrate depicted by formula A, a pharmaceutically acceptable alkali metal salt thereof or a hydrate of the alkali metal salt in the preparation of a medicament for treating acute lung injury or acute respiratory distress syndrome.

Abstract: Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

Abstract: The present invention relates to a benzamide derivative of general formula I, a drug composition containing same and a use thereof as a drug, wherein the definitions of R1, Z and Q are as described in the description.

Abstract: Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

Abstract: Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

Abstract: The present invention relates to a benzamide derivative of general formula I, a drug composition containing same and a use thereof as a drug, wherein the definitions of R1, Z and Q are as described in the description.

Abstract: Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug.

Abstract: The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to 65% of a emulsifying agent, together with various excipients as required depending on the desired dosage forms. The present invention significantly increases the contact area between butylphthalide and the mucous membrane of the gastrointestinal tract, and therefore improves the absorptivity of the drug.

Abstract: The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to 65% of a emulsifying agent, together with various excipients as required depending on the desired dosage forms. The present invention significantly increases the contact area between butylphthalide and the mucous membrane of the gastrointestinal tract, and therefore improves the absorptivity of the drug.